Related Experiment Videos
[Status epilepticus in children. Experience with intravenous valproate. Update of treatment guidelines]
J Campistol1, A Fernández, J Ortega
1Servicio de Pediatría, Hospital Universitari Sant Joan de Déu, Barcelona, España.
Insights
Rectal diazepam and intravenous sodium valproate offer effective treatment for pediatric seizures and status epilepticus. This study introduces a new treatment protocol for childhood seizure emergencies.
Area of Science:
- Neurology
- Pediatric Emergency Medicine
Context:
- Seizures and status epilepticus are neurological emergencies requiring prompt intervention.
- Traditional treatments like rectal diazepam have advanced acute seizure management.
Purpose:
- To present a novel treatment protocol for childhood seizures and status epilepticus.
- To evaluate the efficacy and safety of intravenous sodium valproate in pediatric patients.
Summary:
- Intravenous sodium valproate (20 mg/kg loading dose, 1 mg/kg/hr maintenance) controlled status epilepticus in 58% of 19 pediatric patients (1 day-7 years).
- An additional 26% experienced a reduction in seizure status.
- Treatment was well-tolerated with no significant adverse effects observed.
Impact:
- This protocol offers a new therapeutic option for managing pediatric status epilepticus.
- Improved patient outcomes in neurological emergencies through evidence-based treatment strategies.
Introduction:
The treatment in the acute phase of seizures and status epilepticus is a neurological emergency situation. Aggressive treatment and resuscitation maneuvers against the seizure may be required to avoid progression towards status epilepticus, with the high risk for the patients outcome this involves.
Development:
The use of rectal diazepam has supposed a great advance in the management of acute seizures. Intravenous sodium valproate has become available in these last years to control seizures and status epilepticus. Given at 20 mg/kg as single dose and with maintenance rate of 1 mg/kg/hour by intravenous infusion in 19 paediatric patients (1 day-7 years) status epilepticus was controlled in 58%, with reduction of status in 26%. Tolerance was good and there was no evidence of important adverse effects.
Conclusion:
In view of our experience, we present a new protocol for the treatment of seizures and status epilepticus in childhood.